Jia-Chian Hu

Mar 4, 2024 | jamanetwork.com | Shih-Chieh Shao |Daniel Tsai |Albert Tzu-Ming Chuang |Jia-Chian Hu

Key PointsQuestion  Is the use of sodium-glucose cotransporter 2 (SGLT2) inhibitors associated with reduced risk of anemia in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD) stages 1 to 3? Findings  In this cohort study with 13 799 participants, initiation of SGLT2 inhibitors was associated with a 19% decrease in incident anemia risk compared with initiation of glucagon-like peptide-1 receptor agonists.